Screener
ADMA Biologics ADMA Plasma Collection Centers — Stock-Based Comp
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| (in thousands) | ADMA Bio Manufacturing | Plasma Collection Centers | Total |
|---|---|---|---|
| Revenues | $$123,637 | $723 | 124,360 |
| Cost of product revenue | 37,564 | 554 | 38,118 |
| Research and development | 6,014 | - | 6,014 |
| Plasma center operating expenses | - | 1,026 | 1,026 |
| Gain on sale of plasma centers | - | - | - |
| Selling, marketing and distribution | 7,634 | - | 7,634 |
| Depreciation and amortization expense | 1,281 | 499 | 1,780 |
| General and administrative expense | 8,340 | - | 8,340 |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's plasma collection centers — stock-based comp?
- ADMA Biologics (ADMA) reported plasma collection centers — stock-based comp of $1.03M in Q2 2026.
- What does plasma collection centers — stock-based comp mean?
- Reflects the non-cash expense related to equity-based awards granted to employees specifically supporting the plasma collection segment. This metric is used to understand the true labor cost and alignment of incentives within the segment. It is often excluded from adjusted EBITDA to show cash-based operational performance.
Ask your AI about ADMA Biologics's plasma collection centers — stock-based comp.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude